Inflammatory and Cholesterol Risk in the FOURIER Trial

Bohula, Erin A., Giugliano, Robert P., Leiter, Lawrence A., Verma, Subodh, Park, Jeong-Gun, Sever, Peter S., Lira Pineda, Armando, Honarpour, Narimon, Wang, Huei, Murphy, Sabina A., Keech, Anthony, Pedersen, Terje R., Sabatine, Marc S.·2018·Circulation

DOI 10.1161/circulationaha.118.034032

Cited by (280)

Items 101–200 of 280

High-sensitivity CRP may be a marker of HDL dysfunction and remodeling in patients with acute coronary syndrome
Xiaoyu Tang, Ling Mao, Jin Chen, Tianhua Zhang, Shuwei Weng, Xin Guo, Jie Kuang, Bilian Yu, Daoquan Peng · 2021 · Scientific Reports
Secondary Cardiovascular Prevention after Acute Coronary Syndrome: Emerging Risk Factors and Novel Therapeutic Targets
Angelo Silverio, Francesco Paolo Cancro, Luca Esposito, Michele Bellino, Debora D’Elia, Monica Verdoia, Maria Giovanna Vassallo, Michele Ciccarelli, Carmine Vecchione, Gennaro Galasso et al. · 2023 · Journal of Clinical Medicine
PCSK9 Inhibitors: Clinical Relevance, Molecular Mechanisms, and Safety in Clinical Practice
Filipe Ferrari, Ricardo Stein, Marcelo Trotte Motta, Emílio Hideyuki Moriguchi · 2019 · Arquivos Brasileiros de Cardiologia
The Pleiotropic Effects of Lipid-Modifying Interventions: Exploring Traditional and Emerging Hypolipidemic Therapies
Dimitris C. Kounatidis, Nikolaοs Tentolouris, Natalia G. Vallianou, Iordanis S. Mourouzis, Ιrene Karampela, Theodora Stratigou, Eleni Rebelos, Marina Kouveletsou, Vasileios Stamatopoulos, Eleni Tsaroucha et al. · 2024 · Metabolites
The relationship between residual cholesterol risk and plaque characteristics in patients with acute coronary syndrome: Insights from an optical coherence tomography study
Yanan Gao, Yake Lou, Yuyang Liu, Sijing Wu, Ziwei Xi, Xu Wang, Yujie Zhou, Wei Liu · 2020 · Atherosclerosis
C-reactive protein-to-serum albumin ratio as a novel predictor of long-term outcomes in coronary artery disease patients who have undergone percutaneous coronary intervention: analysis of a real-world retrospective cohort study
Zhiyu Liu, Junnan Tang, Meng-Die Cheng, Li-Zhu Jiang, Qianqian Guo, Jianchao Zhang, Zeng-Lei Zhang, Feng-Hua Song, Kai Wang, Lei Fan et al. · 2021 · Coronary Artery Disease
Low-density lipoprotein cholesterol lowering for the prevention of cardiovascular outcomes in patients with ischemic stroke
George Ntaios, Haralampos J. Milionis · 2019 · International Journal of Stroke
Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial
André Zimerman, Ana Laura Fischer Kunzler, Brittany Weber, Xinhui Ran, Sabina A. Murphy, Huei Wang, Narimon Honarpour, ANTHONY C. KEECH, Peter S. Sever, Marc Steven Sabatine et al. · 2025 · Circulation
A cVLP-Based Vaccine Displaying Full-Length PCSK9 Elicits a Higher Reduction in Plasma PCSK9 Than Similar Peptide-Based cVLP Vaccines
Louise Goksøyr, Magdalena Skrzypczak, Maureen L. Sampson, Morten Agertoug Nielsen, Ali Salanti, Thor Grundtvig Theander, Alan Thomas Remaley, Willem Adriaan de Jongh, Adam Frederik Sander · 2022 · Vaccines
Influence of lipid-lowering drugs on inflammation: what is yet to be done?
Sabina Ugovšek, Janja Zupan, Andreja Rehberger Likozar, Miran Šebeštjen · 2021 · Archives of Medical Science
Association of triglyceride-rich lipoprotein-cholesterol with recurrent cardiovascular events in statin-treated patients according to different inflammatory status
Huihui Liu, Sha Li, Ye‐Xuan Cao, Yuan‐Lin Guo, Cheng‐Gang Zhu, Na‐Qiong Wu, Jian‐Jun Li · 2021 · Atherosclerosis
New Approaches for the Prevention and Treatment of Cardiovascular Disease: Focus on Lipoproteins and Inflammation
Aliza Hussain, Christie Mitchell Ballantyne · 2020 · Annual Review of Medicine
Anti-inflammatory Treatment and Cardiovascular Outcomes: Results of Clinical Trials
Alberto J. Lorenzatti · 2021 · European Cardiology Review
Using Machine Learning to Evaluate the Role of Microinflammation in Cardiovascular Events in Patients With Chronic Kidney Disease
Xiao Qi Liu, Ting Jiang, Meng Ying Wang, Wen Tao Liu, Yang Huang, Yü Huang, Feng Yong Jin, Qing Zhao, Gui Hua Wang, Xiong Zhong Ruan et al. · 2022 · Frontiers in Immunology
Discordance Between Neutrophil to Lymphocyte Ratio and High Sensitivity C-Reactive Protein to Predict Clinical Events in Patients with Stable Coronary Artery Disease: A Large-Scale Cohort Study
Jining He, Chenxi Song, Rui Zhang, Sheng Yuan, Jian‐Jun Li, Kefei Dou · 2023 · Journal of Inflammation Research
Significance of Persistent Inflammation in Patients With Chronic Coronary Syndrome
Hiroshi Iwata, Katsumi Miyauchi, Ryo Naito, Satoshi Iimuro, Yukio Ozaki, Ichiro Sakuma, Yoshihisa Nakagawa, Kiyoshi Hibi, Takefui Hiro, Yoshihiro Fukumoto et al. · 2024 · JACC Advances
Prognostic Impact of High-Sensitivity C-Reactive Protein in Patients Undergoing Percutaneous Coronary Intervention According to BMI
Niklas Beyhoff, Davide Cao, Roxana Mehran, George Dangas, Usman Baber, Samantha Sartori, Moritz Blum, Anastasios Roumeliotis, Rishi Chandiramani, Ridhima Goel et al. · 2020 · JACC: Cardiovascular Interventions
The role of proprotein convertase subtilisin/kexin 9 (PCSK9) in macrophage activation: a focus on its LDL receptor-independent mechanisms
Shunsuke Katsuki, Prabhash Kumar Jha, Elena Aïkawa, Masanori Aikawa · 2024 · Frontiers in Cardiovascular Medicine
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients Following Acute Coronary Syndromes: From Lipid Lowering and Plaque Stabilization to Improved Outcomes
Kyriakos S. Dimitriadis, Nikolaos Pyrpyris, Panagιotis Iliakis, Eirini Beneki, Eleni Adamopoulou, Aggelos Papanikolaou, D. Konstantinidis, Christos Fragkoulis, Αναστάσιος Κόλλιας, Konstantinos A. Aznaouridis et al. · 2024 · Journal of Clinical Medicine
Cholesterol and inflammation: The lesser the better in atherothrombosis
Viviane Zorzanelli Rocha, Raul Dias Santos · 2018 · European Journal of Preventive Cardiology
High risk of subclinical atherosclerosis in COPD exacerbator phenotype
Adolfo Doménech, Ana Muñoz Montiel, Natalia García‐Casares, José Rioja, Pedro Ruiz Esteban, Patricia Gutiérrez Castaño, María Jesús Prunera Pardell, Casilda Olveira, Pedro Valdivielso, Miguel Ángel Sánchez-Chaparro · 2018 · Respiratory Medicine
Interleukin-6 modifies Lipoprotein(a) and oxidized phospholipids associated cardiovascular disease risk in a secondary prevention cohort
Niekbachsh Mohammadnia, Amber van Broekhoven, Willem A. Bax, John W. Eikelboom, Arend Mosterd, Aernoud T.L. Fiolet, Jan G.P. Tijssen, Peter L. Thompson, Dominique P.V. de Kleijn, Sotirios Tsimikas et al. · 2025 · Atherosclerosis
An updated review of lipid‐modifying therapy
Leon A. Simons · 2019 · The Medical Journal of Australia
Residual Inflammation Indicated by High-Sensitivity C-Reactive Protein Predicts Worse Long-Term Clinical Outcomes in Japanese Patients after Percutaneous Coronary Intervention
Norihito Takahashi, Tomotaka Dohi, Hirohisa Endo, Takehiro Funamizu, Hideki Wada, Shinichiro Doi, Yoshiteru Kato, Manabu Ogita, Iwao Okai, Hiroshi Iwata et al. · 2020 · Journal of Clinical Medicine
Prognostic significance of inflammation in patients with coronary artery disease at low residual inflammatory risk
Tianyu Li, Peizhi Wang, Xiaozeng Wang, Zhenyu Liu, Zheng Zhang, Yongzhen Zhang, Zhifang Wang, Yingqing Feng, Qingsheng Wang, Xiaogang Guo et al. · 2023 · iScience
The combined effect of triglyceride–glucose index and high‐sensitivity C ‐reactive protein on cardiovascular outcomes in patients with chronic coronary syndrome: A multicenter cohort study
Qinxue Li, Ying Song, Zheng Zhang, Jingjing Xu, Zhenyu Liu, Xiaofang Tang, Xiaozeng Wang, Yan Chen, Yongzhen Zhang, Pei Zhu et al. · 2024 · Journal of Diabetes
Impact of co-presence of malnutrition-inflammation-atherosclerosis factors on prognosis in lower extremity artery disease patients after endovascular therapy
Kenta Ohmure, Daisuke Kanda, Yoshiyuki Ikeda, Akihiro Tokushige, Takeshi Sonoda, Ryo Arikawa, Kazuhiro Anzaki, Mitsuru Ohishi · 2024 · Cardiovascular Intervention and Therapeutics
Cardioprotective strategies in myocardial ischemia-reperfusion injury: Implications for improving clinical translation
Chao Tong, Bingying Zhou · 2024 · Journal of Molecular and Cellular Cardiology Plus
A tale of two therapies lipid-lowering vs. anti-inflammatory therapy: a false dichotomy?
Timo E. Strandberg, Peter Libby, Petri T. Kovanen · 2020 · European Heart Journal - Cardiovascular Pharmacotherapy
Drug Discovery for Coronary Artery Disease
Qing Wan, Siyuan Qian, Huang Yonghu, Yuze Zhang, Zekun Peng, Qiaoling Li, Bingyan Shu, Liyuan Zhu, Miao Wang · 2020 · Advances in experimental medicine and biology
Effects of PCSK9 Inhibition on Coronary Atherosclerosis Regression of Nontarget Lesions after Primary Percutaneous Coronary Intervention in Acute Coronary Syndrome Patients
Yongjun Li, Mingming Yang, Xi Chen, Rui Zhang, Jing Li, Xiaoguo Zhang, Pengfei Zuo, Genshan Ma · 2022 · Journal of Interventional Cardiology
PCSK9 Inhibition in Atherosclerotic Cardiovascular Disease
Dimitrios Delialis, Maria‐Angeliki Dimopoulou, Maria Papaioannou, Georgia Kotsira, Eleni Maneta, Georgios Mavraganis, Christos Loutos, Georgios A. Georgiopoulos, Kimon S. Stamatelopoulos · 2023 · Current Pharmaceutical Design
Postnatal exposure to hypobaric hypoxia and its impact on inflammation and injury indexes after a cardiac valve procedure
Qin Jiang, Hanyu Li, Xiyu Huang, Lu Yu, Sabrina Lueck, Shengshou Hu · 2020 · Interactive Cardiovascular and Thoracic Surgery
Proprotein convertase subtilisin/kexin type 9 inhibition as the next statin?
Günaj Rakipovski, G. Kees Hovingh, Michael Nyberg · 2020 · Current Opinion in Lipidology
Persistent inflammatory residual risk despite aggressive cholesterol-lowering therapy: further evidence fuelling the dual target concept
Wolfgang Köenig · 2020 · European Heart Journal
IMPACT of PCSK9 inhibition on clinical outcome in patients during the inflammatory stage of the SARS-COV-2 infection: Rationale and protocol of the IMPACT-SIRIO 5 study
Jacek Kubica, Przemysław Podhajski, Przemysław Magielski, Aldona Kubica, Piotr Adamski, Roman Junik, Jarosław Pinkas, Eliano Pio Navarese · 2021 · Cardiology Journal
Key Roles of Inflammation in Atherosclerosis: Mediators Involved in Orchestrating the Inflammatory Response and Its Resolution in the Disease Along with Therapeutic Avenues Targeting Inflammation
Yee‐Hung Chan, Dipak P. Ramji · 2022 · Methods in molecular biology
Inflammation and Thrombosis in Coronary Atherosclerosis: Pathophysiologic Mechanisms and Clinical Correlations
John A. Ambrose, Amarbir Singh Bhullar · 2019 · European Medical Journal
High-Sensitivity C-Reactive Protein and Residual Inflammatory Risk in Coronary Artery Disease: The Pathophysiology, Prognosis, and Emerging Therapies
Masahiro Katamine, Yoshiyasu Minami, Junya Ako · 2025 · Journal of Atherosclerosis and Thrombosis
Circulating Autoantibodies Recognizing Immunodominant Epitopes From Human Apolipoprotein B Associate With Cardiometabolic Risk Factors, but Not With Atherosclerotic Disease
Timoteo Marchini, Sara Malchow, Lourdes Cáceres, Abed Al Hadi El Rabih, Sophie Hansen, Timothy Bon-Nawul Mwinyella, Lisa Spiga, Sven M. Piepenburg, Hauke Horstmann, Tijani Abogunloko et al. · 2022 · Frontiers in Cardiovascular Medicine
PCSK9 inhibitors for anti-inflammation in atherosclerosis: protocol for a systematic review and meta-analysis of randomised controlled trials
Jichang Luo, Wanying Liao, Xue Wang, Ran Xu, Wei Li, Wenjing Li, Kan Liu, Kaixun Huang, Yan Ma, Tao Wang et al. · 2022 · BMJ Open
Inhibition of PCSK9 with evolocumab modulates lipoproteins and monocyte activation in high-risk ASCVD subjects
Robert S. Rosenson, Ashley Tate, Phyu Mar, Olga G. Grushko, Qinzhong Chen, Sascha N. Goonewardena · 2024 · Atherosclerosis
Lipids and Inflammation: Novel Molecular Targets and Therapeutic Implications
Laura Torlai Triglia, Filippo Luca Gurgoglione, Federico Barocelli, Michele Bianconcini, Giampaolo Niccoli · 2024 · Current Medicinal Chemistry
Monoclonal Antibodies, Gene Silencing and Gene Editing (CRISPR) Therapies for the Treatment of Hyperlipidemia—The Future Is Here
Melody Hermel, Madison Lieberman, Leandro N. Slipczuk, Jamal S. Rana, Salim S. Virani · 2023 · Pharmaceutics
Atherosklerose als inflammatorische Erkrankung – Pathophysiologie, klinische Relevanz und therapeutische Implikationen
Natalie Arnold, Wolfgang Köenig · 2019 · DMW - Deutsche Medizinische Wochenschrift
Targeting the peptidase PCSK9 to reduce cardiovascular risk: Implications for basic science and upcoming challenges
Toshiyuki Nishikido, Kausik Kumar Ray · 2019 · British Journal of Pharmacology
Prediction and early detection of cardiovascular disease in South Asians with diabetes mellitus
Gagandeep Singh Wander, Manish Bansal, Ravi Ratan Kasliwal · 2020 · Diabetes & Metabolic Syndrome Clinical Research & Reviews
Comparison of high-sensitivity C-reactive protein vs. C-reactive protein for diagnostic accuracy and prediction of mortality in patients with acute myocardial infarction
Felix Hofer, Thomas Perkmann, Gloria M. Gager, Max‐Paul Winter, Alexander Niessner, Christian Hengstenberg, Jolanta Maria Siller-Matula · 2021 · Annals of Clinical Biochemistry International Journal of Laboratory Medicine
Association of residual inflammatory risk with stroke recurrence in patients with acute ischaemic stroke or transient ischaemic attack
Huihui Liu, Mengxing Wang, Xianglong Xiang, Yuesong Pan, Jiejie Li, Xia Meng, Hao Li, Zixiao Li, Jing Jing, Yongjun Wang · 2022 · European Journal of Neurology
Precision Medicine in Acute Coronary Syndromes
Andrea Caffè, Francesco Maria Animati, Giulia Iannaccone, Riccardo Rinaldi, Rocco Antonio Montone · 2024 · Journal of Clinical Medicine
Improving diagnostic assessments in the ever-changing landscape of atherosclerosis
Angel López‐Candales, Khalid Sawalha · 2023 · Journal of Cardiovascular Medicine
Biologic bases of residual risk of cardiovascular events: A flawed concept
Michael David Shapiro, Sergio Fazio · 2018 · European Journal of Preventive Cardiology
Impact of preprocedural biological markers on 10-year mortality in the SYNTAXES trial
Hironori Hara, Hideyuki Kawashima, Masafumi Ono, Kuniaki Takahashi, Michael Mack Mack, David R. Holmes, Marie-Claude Morice, Piroze Davierwala Davierwala, Friedrich Wilhelm Mohr, Daniel Thuijs Thuijs et al. · 2022 · EuroIntervention
Proprotein convertase subtilisin/kexin type 9: an update on the cardiovascular outcome studies
Nicola Ferri, Maria Francesca Greco, Alberto Corsini, Massimiliano Ruscica · 2020 · European Heart Journal Supplements
Efficacy and safety of add on therapies in patients with hypercholesterolemia undergoing statin therapy
Brian Tomlinson, Paul Chan, Yuzhen Zhang, Christopher Wai Kei Lam · 2020 · Expert Opinion on Pharmacotherapy
Evaluación y manejo del riesgo cardiovascular residual en el paciente con diabetes
José Antonio Gimeno Orna, José Jorge Ortez Toro, Carlos Miguel Peteiro Miranda · 2019 · Endocrinología Diabetes y Nutrición
Admission Low-Density Lipoprotein Cholesterol Stratified by Circulating CD14++CD16+ Monocytes and Risk for Recurrent Cardiovascular Events Following ST Elevation Myocardial Infarction: Lipid Paradox Revised
Shaozhuang Dong, Wenjie Ji, Shan Zeng, Jun Miao, Li-Fang Yan, Xinlin Liu, Junxiang Liu, Xin Zhou, Qing Yang · 2020 · Journal of Cardiovascular Translational Research
Clinical implications of the log linear association between LDL-C lowering and cardiovascular risk reduction: Greatest benefits when LDL-C >100 mg/dl
Jennifer G. Robinson, Manju Bengaluru Jayanna, C. Noel Bairey Merz, Neil J. Stone · 2020 · PLoS ONE
CARotid plaqUe StabilizatiOn and regression with evolocumab: Rationale and design of the CARUSO study
Tiziana Claudia Aranzulla, Salvatore Piazza, Andrea Ricotti, Giuseppe Musumeci, Andrea Gaggiano · 2021 · Catheterization and Cardiovascular Interventions
The Ratio of Triglyceride to High-density Lipoprotein Cholesterol as an Indicator of Risk Stratification for Atherosclerotic Cardiovascular Disease in a Clinical Setting
Shigemasa Tani · 2020 · Internal Medicine
A bibliometric analysis of PCSK9 inhibitors from 2007 to 2022
Qin Luo, Zhenchu Tang, Panyun Wu, Zhangling Chen, Zhenfei Fang, Fei Luo · 2023 · Frontiers in Endocrinology
Biomarkers of residual risk and all-cause mortality after acute coronary syndrome.
Anna Toso, Mario Leoncini, Mauro Maioli, Simona Villani, Francesco Bellandi · 2025 · American Journal of Preventive Cardiology
Key inflammatory players for infarcted mass and cardiac remodeling after acute myocardial infarction
Francisco Antônio Helfenstein Fonseca, Carolina Nunes França, Henrique Andrade R. Fonseca, Andrey Jorge Serra, Maria Cristina de Oliveira Izar · 2025 · Frontiers in Cardiovascular Medicine
Cholesterol-Inflammation Fusion Hypothesis in Atherosclerosis
Rui‐Xiang Zeng, Sha Li, Jian‐Jun Li · 2026 · JACC Asia
Determination of Serum Progranulin in Patients with Untreated Familial Hypercholesterolemia
Bíborka Nádró, Hajnalka Lőrincz, Lilla Juhász, Anita Szentpéteri, Ferenc Sztanek, Éva Varga, Dénes Páll, György Paragh, Mariann Harangi · 2022 · Biomedicines
Targeting high-sensitivity C-reactive protein levels in acute coronary syndrome patients undergoing contemporary lipid-lowering therapy: a sub-analysis of the HIJ-PROPER trial
Erisa Kawada‐Watanabe, Junichi Yamaguchi, Haruki Sekiguchi, Hiroyuki Arashi, Hiroshi Ogawa, Nobuhisa Hagiwara · 2019 · Journal of Cardiology
Pre‐Percutaneous Coronary Intervention C‐Reactive Protein Levels and In‐Stent Restenosis: A Systematic Review and Meta‐Analysis
Himanshu Rai, Renitha Reddi, John Joseph Coughlan, Rory Durand, Daniel O’Callaghan, Róisín Colleran, Robert A. Byrne · 2025 · Health Science Reports
The Contribution of Inflammation to Stroke Recurrence Attenuates at Low LDL-C Levels
Xing Zhang, Wei Lv, Jie Xu, Jiejie Li, Yuesong Pan, Hongyi Yan, Hao Li, Zixiao Li, Xia Meng, Yongjun Wang · 2022 · Journal of Atherosclerosis and Thrombosis
Post-PCI Risk Assessment by Inflammation Activity According to Disease Acuity and Time from Procedure
Hae‐Geun Song, Jong‐Hwa Ahn, Min Gyu Kang, Kyehwan Kim, Jae Seok Bae, Sang Young Cho, Jin‐Sin Koh, Yongwhi Park, Seok‐Jae Hwang, Eun Jeong Cho et al. · 2023 · Thrombosis and Haemostasis
Colchicine and cardiovascular prevention
Alessia Alunno, Francesco Carubbi, Claudio Ferri · 2024 · European Journal of Internal Medicine
PCSK9: The Nexus of Lipoprotein Metabolism and Inflammation in COVID-19
Sascha N. Goonewardena, Robert S. Rosenson · 2023 · Journal of the American College of Cardiology
Pleiotropic Effects of PCSK9 Inhibitors on Cardio-Cerebrovascular Diseases
Zhenzhen Li, Lin Zhu, Yeqiong Xu, Yiting Zhang, Yukai Liu, Huiling Sun, Shuo Li, Meng Wang, Teng Jiang, Junshan Zhou et al. · 2024 · Biomedicines
Perceptions of high-sensitivity C-reactive protein testing (hsCRP) in atherosclerotic cardiovascular disease: a US survey on cardiologists and nephrologists
Lei Lv, Ty J. Gluckman, Matthew W. Strum, Jigar R. Rajpura · 2025 · Future Cardiology
High-Sensitivity C-Reactive Protein is a Predictor of Subsequent Atrial High-Rate Episodes in Patients with Pacemakers and Preserved Ejection Fraction
Min‐Tsun Liao, Chun‐Kai Chen, Ting‐Tse Lin, Li-Ying Cheng, Hung-Wen Ting, Yen‐Bin Liu · 2020 · Journal of Clinical Medicine
Bempedoic Acid: The New Kid on the Block for the Treatment of Dyslipidemia and LDL Cholesterol: A Narrative Review
Uazman Alam, Dalal Y. Al-Bazz, Handrean Soran · 2021 · Diabetes Therapy
Redefining Residual Inflammatory Risk After Acute Coronary Syndrome
Marco Giuseppe Del Buono, Rocco Antonio Montone, Giulia Iannaccone, Riccardo Rinaldi, Giulia La Vecchia, Massimiliano Camilli, Filippo Luca Gurgoglione, Michele Russo, Marco Lombardi, D D'Amario et al. · 2021 · Future Cardiology
Main differences between two highly effective lipid-lowering therapies in subclasses of lipoproteins in patients with acute myocardial infarction
Leticia C. S. Pinto, Ana Paula de Queiroz Mello, Maria Cristina de Oliveira Izar, Nágila Raquel Teixeira Damasceno, A. M. Figueiredo Neto, Carolina Nunes França, Adriano Mendes Caixeta, Henrique Tria Bianco, Rui Póvoa, Flávio Tocci Moreira et al. · 2021 · Lipids in Health and Disease
Tyramine exerts hypolipidemic and anti-obesity effects in vivo
Thamires Maria Fontenele Morais, Tiago Sousa de Melo, Mariana Brito Dantas, Jamile Magalhães Ferreira, Daniel Freire de Sousa, Emanuel Paula Magalhães, Ramon Róseo Paula Pessoa Bezerra de Menezes, Otília Deusdênia Loiola Pessoa, Mariana Lima Feitosa, Francisca Cléa Florenço de Sousa et al. · 2022 · Brazilian Journal of Pharmaceutical Sciences
Strategies for the Secondary Prevention of Atherosclerotic Cardiovascular Disease
Madelyn Hurwitz, Olayinka J Agboola, Abhishek Gami, Marlene S. Williams, Salim S. Virani, Garima V. Sharma, Jaideep Patel · 2025 · US Cardiology Review
Impact of pericoronary adipose tissue attenuation on clinical outcomes after percutaneous coronary intervention
Shota Naniwa, Hiroyuki Kawamori, Takayoshi Toba, Takashi Hiromasa, Yoichiro Sugizaki, Satoru Sasaki, Hiroyuki Fujii, Tomoyo Hamana, Yuto Osumi, Tetsuya Yamamoto et al. · 2025 · EuroIntervention
Novel targets and strategies addressing residual cardiovascular risk in post-acute coronary syndromes patients
Francesco Paolo Cancro, Michele Bellino, Angelo Silverio, Marco Di Maio, Luca Esposito, Rossana Palumbo, Martina Manna, Ciro Formisano, Germano Junior Ferruzzi, Carmine Vecchione et al. · 2024 · Translational Medicine UniSa
C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOV
Adam J. Nelson, Rishi Puri, Danielle M. Brennan, Todd J. Anderson, Leslie Cho, Christie Mitchell Ballantyne, John J.P. Kastelein, Wolfgang Köenig, Helina Kassahun, Ransi M. Somaratne et al. · 2020 · American Journal of Preventive Cardiology
Tratamiento hipolipemiante en los pacientes con enfermedad cardiovascular de riesgo muy elevado. Documento de consenso SEC sobre las indicaciones de los iPCSK9 en la práctica clínica
Angel R. Cequier, Vicente Arrarte, Raquel Campuzano, Almudena Castro, Alberto Cordero, María Rosa Fernández Olmo, Xavier García–Moll, Juan José Gómez‐Doblas, Esteban López de Sá, Julio E. Núñez et al. · 2020 · REC CardioClinics
How to Interpret Recent CV Outcome Trials and Future: PCSK9 Inhibitors
Eun Young Lee, Kun‐Ho Yoon · 2018 · Journal of Lipid and Atherosclerosis
Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity C-Reactive Protein in Patients With Previous Myocardial Infarction
Ye‐Xuan Cao, Sha Li, Huihui Liu, Meng Zhang, Yuan‐Lin Guo, Na‐Qiong Wu, Cheng‐Gang Zhu, Qian Dong, Jing Sun, Kefei Dou et al. · 2022 · Frontiers in Cardiovascular Medicine
Association of triglyceride-glucose index with adverse cardiovascular events in patients with established coronary artery disease according to different inflammatory status
Zhangyu Lin, Jining He, Chenxi Song, Sheng Yuan, Yanjun Song, Xiaohui Bian, Kefei Dou · 2024 · Nutrition Metabolism and Cardiovascular Diseases
Effect of cholesterol re-supplementation and atorvastatin on plaque composition in the thoracic aorta of New Zealand white rabbits
Gabriel A. Bonaterra, K. Bender, B. Wilhelm, Hans Schwarzbach, Stephan Metz, Olaf Kelber, Dieter Weiser, J. Metz, Ralf Kinscherf · 2020 · BMC Cardiovascular Disorders
Distinct pathological mechanisms distinguish acute coronary syndrome caused by plaque erosion from plaque rupture
Denitsa Meteva, Claudio Seppelt, Youssef S. Abdelwahed, David M. Leistner · 2021 · Current Opinion in Cardiology
Clinical impact of systemic inflammation across different high-sensitivity C-reactive protein cutoffs in patients undergoing percutaneous coronary intervention
Angelo Oliva, Mark Shneyderman, Mauro Gitto, Samantha Sartori, Birgit Vogel, Benjamin Bay, Kenneth F. Smith, Pedro Moreno, Joseph Michael Sweeny, Francesca Maria Di Muro et al. · 2025 · Atherosclerosis
LDL receptor-independent mechanisms of proprotein convertase subtilisin/kexin type 9 in cardiovascular pathophysiology
HANG SU, Xunan Guo, Qiang Li, Xiaohang Yuan, Xiaolong Wu, Zihan Zhao, Yi Kan, Yifan Yang, Zhaolin Fu, Zhenrui Qi et al. · 2026 · Frontiers in Cardiovascular Medicine
PCSK9 molecular bridge between hyperlipidemia and vascular inflammation: novel insights into PCSK9-centered pathways in atherosclerosis: a comprehensive review
Muhammad A. Desouky, Mohammed A. El‐Magd, Mohamed Abdelmeguid Mousa, Abbas Hayat Mallick, Delwar Khan, Dina A. Desouky · 2025 · Beni-Suef University Journal of Basic and Applied Sciences
High-sensitivity C-reactive protein is associated with altered cardiac structure and function in psoriasis: The PSOCADIA study
Maria Dons, Morten Sengeløv, Kristoffer Grundtvig Skaarup, Niklas Dyrby Johansen, Mats Christian Højbjerg Lassen, Sofie Bøgh‐Sørensen, Julie Borchsenius, Filip Soeskov Davidovski, Nino Emanuel Landler, C. Nissen et al. · 2025 · IJC Heart & Vasculature
Inflammation—The new treatment target for ischaemic stroke prevention
Sarah Gorey, John Joseph McCabe, Peter J. Kelly · 2023 · Frontiers in Stroke
Targeting PCSK9 beyond the liver: evidence from experimental and clinical studies
Lorenzo Da Dalt, Andrea Baragetti, Giuseppe Danilo Norata · 2025 · Expert Opinion on Therapeutic Targets
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and the Risk of Fracture: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Fang Lv, Xiaoling Cai, Chu Lin, Wenjia Yang, Suiyuan Hu, Linong Ji · 2023 · Calcified Tissue International
Longitudinal correlation between cumulative remnant cholesterol inflammatory index and incident diabetes
Qiqiang Li, Li Gong, Hongxin Li · 2025 · Diabetology & Metabolic Syndrome
A short review of proprotein convertase subtilisin/kexin type 9 inhibitors
Rudaynah A. Alali · 2019 · Reviews in Cardiovascular Medicine
Overall Mortality and LDL Cholesterol Reduction in Secondary Prevention Trials of Cardiovascular Disease
Expert group from the Spanish Arteriosclerosis Society, Juan Pedro‐Botet, José López‐Miranda, Lina Badimón, Fernando Civeira, Carlos Guijarro, Jesús Millán, José M. Mostaza, Xavier Pintó, Pedro Valdivielso et al. · 2019 · American Journal of Cardiovascular Drugs
Residual risk in patients with atherosclerotic cardiovascular disease
Elena Vladimirovna Khazova, O. V. Bulashova · 2023 · CARDIOVASCULAR THERAPY AND PREVENTION
Targeting leukotriene biosynthesis to prevent atherosclerotic cardiovascular disease.
Xiaomeng Wang, Lohendran Baskaran, Mark Y. Chan, William A. Boisvert, Derek John Hausenloy · 2023 · PubMed